MedTrace Logo

Study of Serum Tumor Markers of HBV Associated HCC

NCT05825196 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 164

Last updated 2023-04-24

No results posted yet for this study

Summary

In this study, the investigators will detect the expression of four potential HBV-related HCC biomarkers: PGIR,FAM3C,LAMB1 and SDC4 in tumor tissues and peripheral blood, to explore the specific molecular markers for the early diagnosis of HBV-related HCC.

Conditions

Interventions

DIAGNOSTIC_TEST

tumor tissue and blood tests

In this study, we need to collect an extra tube of blood for routine testing and the tissue after completion of pathological examination.

Sponsors & Collaborators

  • Qianfoshan Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-05-01
Primary Completion
2025-01-31
Completion
2025-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05825196 on ClinicalTrials.gov